Global Pharmaceutical CMO and CDMO Market Growth (Status and Outlook) 2025-2031

The global Pharmaceutical CMO and CDMO market size is predicted to grow from US$ 155810 million in 2025 to US$ 246800 million in 2031; it is expected to grow at a CAGR of 8.0% from 2025 to 2031.

A CDMO is a company dedicated to providing drug development and manufacturing services for the pharmaceutical and biotechnology industries. CDMO activities can broadly be divided into four fields: product development, manufacture of active pharmaceutical ingredients (API), manufacture of finished dosage forms (FDF) and pharma packaging.

The market driver is consistent development of blockbuster pharmaceuticals, increasing production outsourcing by pharmaceuticals companies. The increasing outsourcing trend in the pharmaceutical industry demonstrates the success of this business model, as CDMOs are increasingly becoming integral parts of pharmaceutical companies’ value chains.

ReportPrime' newest research report, the “Pharmaceutical CMO and CDMO Industry Forecast” looks at past sales and reviews total world Pharmaceutical CMO and CDMO sales in 2024, providing a comprehensive analysis by region and market sector of projected Pharmaceutical CMO and CDMO sales for 2025 through 2031. With Pharmaceutical CMO and CDMO sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Pharmaceutical CMO and CDMO industry.

This Insight Report provides a comprehensive analysis of the global Pharmaceutical CMO and CDMO landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Pharmaceutical CMO and CDMO portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Pharmaceutical CMO and CDMO market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Pharmaceutical CMO and CDMO and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Pharmaceutical CMO and CDMO.

This report presents a comprehensive overview, market shares, and growth opportunities of Pharmaceutical CMO and CDMO market by product type, application, key players and key regions and countries.

Segmentation by Type:

• API CMO and CDMO
• FDF CMO and CDMO
• Packaging CMO
• Clinical CDMO

Segmentation by Application:

• Pharmaceutical Company
• Biotechnology Company
• Other

Market by Region:

• Americas
• APAC
• Europe
• Middle East & Africa

Company Coverage:

• Lonza
• Catalent
• Thermo Fisher Scientific
• Samsung Biologics
• Fareva
• WuXi AppTech
• WuXi Biologics
• Siegfried
• FUJIFILM Diosynth Biotechnologies
• Asymchem
• Pfizer CentreOne
• Delpharm
• Recipharm
• AGC Pharma Chemicals
• Boehringer Ingelheim
• Vetter
• Curia
• Aenova
• Porton
• Piramal
• Strides Pharma
• NextPharma
• Famar
• Jubilant
• Alcami
• Euroapi
• Eurofins
• Avid Bioservices
• BioVectra
• CPL

Key Questions Addressed in this Report